graph Evidence gap map comparisons
Immune checkpoint associationnivolumab plus ipilimumabImmune checkpoint association
durvalumab plus tremelimumab nivolumab plus ipilimumab nivolumab plus ipilimumab plus SoC pembrolizumab plus ipilimumab
mNSCLC - L1 - all population 5     
mNSCLC - L1 - EGFR mutant
mNSCLC - L1 - PDL1 negative 1
mNSCLC - L1 - PDL1 positive 14       
mNSCLC - L1 - TMB>10Mb 1   
non squamous cell - mNSCLC - L1
non squamous - mNSCLC - L1 - all population 3
non squamous - mNSCLC - L1 - PDL1 positive
non squamous - mNSCLC - L1 - Wild Type (WT) 6
squamous cell - mNSCLC - L1
squamous - mNSCLC - L1 - all population 4
squamous - mNSCLC - L1 - PDL1 positive
squamous - mNSCLC - L1 - Wild Type (WT)
Comparator:  vs Standard of Care (SoC);   vs pemetrexed plus platin;   vs pembrolizumab plus placebo; 
Risk of bias:  low;   some concerns;   high;  NA;